Tilray Brands (TLRY) is back at the center of the cannabis market’s biggest catalyst in years: growing expectations that President Donald Trump could move to ease federal marijuana restrictions by pushing a reclassification of cannabis to Schedule III. On Monday, December 15, 2025, the optimism spilled into global trading, with cannabis names extending last week’s explosive rally as investors tried to price what a Schedule III world could mean for taxes, banking access, and institutional participation.
But Tilray’s move isn’t just about Washington. The company is also coming off a 1-for-10 reverse stock split and fresh product momentum tied to its Canadian cannabis portfolio—fuel for a stock that thrives on narrative-driven volatility.
What happened on December 15: the “Schedule III” trade goes global
In early European trading on Dec. 15, Reuters reported broad strength across cannabis equities, led by Canopy Growth and joined by Tilray and SNDL as the sector extended Friday’s surge. The move followed reports—first highlighted late last week—that Trump is expected to direct federal agencies to pursue reclassifying marijuana as a Schedule III drug, a shift that would loosen federal oversight versus today’s Schedule I status.
The Washington Post described the discussions as an effort to “dramatically loosen” federal restrictions through an executive order directing agencies to pursue reclassification, while also emphasizing an important limit: the move would not legalize or decriminalize marijuana nationwide. The Washington Post+1
That nuance matters for consumers, but for public cannabis companies, Schedule III is still a potential game-changer—because it targets some of the industry’s most painful structural disadvantages.
Why Schedule III matters to cannabis stocks (and why it’s not “legalization”)
Schedule III would not instantly put cannabis on pharmacy shelves or override state-by-state rules. Instead, it would reshape the regulatory and financial landscape that cannabis operators have been navigating for years.
Two expected “big levers” stand out:
- Taxes: A Schedule III shift could ease the burden of federal tax rules that have historically limited deductions for cannabis businesses—one reason profitability has been elusive across the sector. The Washington Post noted that rescheduling could materially improve the bottom lines of legal operators even without nationwide legalization.
- Banking and capital access: Investors have long argued that lower federal risk could make banks, payment processors, and institutions more willing to work with cannabis-linked businesses. Market coverage of the rally has repeatedly tied the move to improved access to traditional financial services.
In other words: Schedule III isn’t the finish line. But it could remove enough friction—on taxes, compliance, and capital—to change the economics of the legal industry.
Tilray’s rally has multiple engines: policy catalyst + corporate reset + product buzz
Tilray’s stock action in mid-December has been a collision of macro catalyst and company-specific developments.
1) The Trump reclassification headlines supercharged the entire group
Reuters reported that cannabis names jumped after the Washington Post story, with Tilray among the prominent movers during Friday’s reaction and the subsequent follow-through.
Barron’s similarly described a sharp move across the cannabis complex tied to the same catalyst and the market’s expectation of lower taxes under a less restrictive scheduling framework.
2) Reverse split aftershocks are amplifying volatility
Tilray implemented a 1-for-10 reverse stock split effective December 1, 2025, with split-adjusted trading beginning December 2. In its announcement, the company framed the move as a way to align shares outstanding with peers, increase institutional appeal, and reduce certain annual costs.
Reverse splits often don’t change a business—but they can change trading behavior. With fewer shares outstanding and a higher post-split price, a stock can become more sensitive to momentum flows, option activity, and headline-driven sentiment.
3) A new vape rollout is giving traders a “fundamental” hook
Tilray also has a tangible operational headline in the mix: Redecan’s launch of “Amped Live Resin Liquid Diamond” 1g 510 cartridges, billed as the brand’s first live resin–liquid diamond line. The company said the launch pairs live resin with “liquid diamonds,” uses an 80%/20% formulation, and will roll out first in Ontario and Alberta, with wider distribution planned for early 2026. GlobeNewswire
Importantly for narrative, Tilray also pointed to category-level demand signals: it cited 6.3% growth in live resin vapes over the past six months and noted that vape penetration tends to peak during the winter months—timing the company argues supports the launch window.
After-hours action: Tilray leads a momentum tape
The sector’s volatility hasn’t been limited to regular trading hours. In a market pulse recap, RTTNews highlighted Tilray as a leader in after-hours action, noting the stock’s sharp move in the context of the recent reverse split and broader “high-volatility” trading in healthcare and cannabis names. RTTNews+1
That matters because it shows how much of Tilray’s price discovery is currently happening in momentum windows—exactly the environment where policy rumors, fast-twitch positioning, and retail flows can dominate.
Valuation: the stock is moving faster than the spreadsheets
The key question for longer-term investors is whether this is a policy-driven overshoot or the start of a durable re-rating.
A valuation-focused write-up on Yahoo Finance flagged that a DCF-style fair value estimate was below where the stock was trading at the time—suggesting Tilray could look slightly overvalued even after factoring in product updates and sentiment.
That doesn’t mean Tilray can’t go higher in a catalyst market. It does mean the bar for “real” fundamental follow-through—margin improvement, balance-sheet clarity, and sustained demand—gets higher once price runs far ahead of cash-flow expectations.
The reality check: what could slow the rally
This week’s catalyst is powerful, but it’s also fragile. Even the most bullish reporting has included caveats:
- No final decision yet: Reuters quoted a White House official saying no final decisions had been made on rescheduling.
- Process and politics: The Washington Post reported Trump can’t unilaterally reclassify marijuana, though he could direct the Justice Department to alter the path of an ongoing administrative process.
- History of hype cycles: Market commentary has warned that cannabis investors have seen “almost there” moments before—where enthusiasm fades when policy timelines stretch. MarketWatch
In the near term, Tilray may trade less like a steady consumer packaged goods operator and more like a policy-sensitive vehicle—moving on probability, headlines, and positioning.
What to watch next (the December 15 checklist)
If you’re tracking Tilray and the cannabis sector into year-end, the next signals likely to matter most are:
- Concrete White House/agency steps on rescheduling (not just reports).
- Follow-through in banking and capital markets rhetoric, including whether institutions shift from “watching” to “participating.” Reuters+1
- Tilray execution post-reverse split—particularly whether product initiatives like Redecan’s vape rollout translate into durable revenue/margin improvements rather than temporary buzz.
For now, December 15 has made one thing clear: cannabis is trading like a sector with a live wire attached to Washington—and Tilray is one of the stocks most directly plugged into that current.
